Free Trial
NASDAQ:MLAB

Mesa Laboratories (MLAB) Stock Price, News & Analysis

$110.02
+1.83 (+1.69%)
(As of 07/26/2024 ET)
Today's Range
$107.10
$111.89
50-Day Range
$84.94
$122.22
52-Week Range
$82.86
$145.46
Volume
49,767 shs
Average Volume
46,034 shs
Market Capitalization
$595.21 million
P/E Ratio
N/A
Dividend Yield
0.58%
Price Target
$106.00

Mesa Laboratories MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3.7% Downside
$106.00 Price Target
Short Interest
Healthy
3.48% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
5.50%
From $6.91 to $7.29 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.11 out of 5 stars

Medical Sector

809th out of 936 stocks

Process Control Instruments Industry

12th out of 13 stocks

MLAB stock logo

About Mesa Laboratories Stock (NASDAQ:MLAB)

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

MLAB Stock Price History

MLAB Stock News Headlines

MESA LABS DECLARES QUARTERLY DIVIDEND
Top Stock Unveiled!
Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories Inc.
See More Headlines
Receive MLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/14 Dividend
5/31/2024
Last Earnings
6/05/2024
Dividend Payable
6/14/2024
Today
7/26/2024
Next Earnings (Estimated)
8/01/2024
Ex-Dividend for 9/16 Dividend
8/30/2024
Dividend Payable
9/16/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Process control instruments
Sub-Industry
Electronic Equipment & Instruments
Current Symbol
NASDAQ:MLAB
CUSIP
59064R10
Employees
680
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$106.00
High Stock Price Target
$106.00
Low Stock Price Target
$106.00
Potential Upside/Downside
-3.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-254,250,000.00
Net Margins
-117.61%
Pretax Margin
-127.50%

Debt

Sales & Book Value

Annual Sales
$216.19 million
Cash Flow
$58.83 per share
Book Value
$26.95 per share

Miscellaneous

Free Float
5,128,000
Market Cap
$595.21 million
Optionable
Not Optionable
Beta
0.86
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

MLAB Stock Analysis - Frequently Asked Questions

How have MLAB shares performed this year?

Mesa Laboratories' stock was trading at $104.77 at the start of the year. Since then, MLAB shares have increased by 5.0% and is now trading at $110.02.
View the best growth stocks for 2024 here
.

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its quarterly earnings data on Wednesday, June, 5th. The medical instruments supplier reported $2.25 EPS for the quarter. The medical instruments supplier earned $58.90 million during the quarter. Mesa Laboratories had a negative net margin of 117.61% and a positive trailing twelve-month return on equity of 10.10%.

What is Gary Owens' approval rating as Mesa Laboratories' CEO?

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' top institutional investors include Raymond James & Associates (1.49%), Bank of New York Mellon Corp (1.08%), Allspring Global Investments Holdings LLC (0.09%) and Sequoia Financial Advisors LLC (0.07%). Insiders that own company stock include John Bradley Schmieder, Gary M Owens, Evan Guillemin, John James Sullivan, John Sakys, Shannon Hall, Brian David Archbold, David M Kelly and Gregory Dinoia.
View institutional ownership trends
.

How do I buy shares of Mesa Laboratories?

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU) and Exxon Mobil (XOM).

This page (NASDAQ:MLAB) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners